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128 Poster Session IIThe detection of naturally occurring T cells responding to pro-
teins overexpressed in myeloid leukemia suggests that vaccines
could boost the immune response to leukemia and achieve disease
control. Human neutrophil elastase (HNE) is a myeloid-restricted
protein highly expressed in myeloid leukemia cells. HNE protein
can induce both CD41 and CD81 T cell responses in healthy in-
dividuals including HLA-A*0201 negative individuals. To develop
HNE protein vaccine, and to identify major histocompatibility
complex (MHC) class II restricted or HLA-A*0201 negative
MHC class I restricted epitopes in HNE, we stimulated peripherial
blood mononuclear cells (PBMC) from 6 myeloid leukemia pre-
transplant patients with purified full length HNE protein. HNE
protein induced a response in CD41 and CD81T cells from 4 pa-
tients with acute myeloid leukemia (AML), as measured by IFN-g
protein expression in flow cytometric assay. However, no response
was detected in CD41 and CD81T cells from 2 pre-transplant pa-
tients with chronic myeloid leukemia (CML). Responses of CD41
and CD81 T cells to HNE protein stimulation were enhanced by
HNE expressing antigen-presenting T cells (T-APC), as measured
by flow cytometric assay. HNE protein induced significant IFN-g
expression in CD41 and CD81 T cells at 540X and 10X above
background in an (HLA-A11, 31) AML patient (patient #1), and
at 6X and 3.5X above background in an (HLA-A*0205, 03*) AML
patient (patient #2), as measured by quantitative Real-Time RT-
PCR assay (QRT-PCR). HNE protein also induced significant
IL-2 production in CD41 and CD81 T cells at 7.7X and 6.1X
above background in patient #1. Finally, we showed by QRT-
PCR that the T cell responses to HNE protein stimulation were
associated with the levels of HNE gene transcripts in the PBMC.
Further inverstigation of the correlation betweenHNEprotein spe-
cific CD41 and CD81T-cell responses and HNE gene transcripts
in consecutive samples obtained pre- and post-SCT may define an
ideal timewindow to vaccinate post-SCTpatients withmyeloid leu-
kemias. We found that full-length HNE protein stimulated both
CD41 and CD81 T cell responses in HLA-A*0201 negative pa-
tients with AML in the first three months following SCT. These re-
sults provide the rationale for using HNE protein to vaccinate
patients with myeloid leukemias after SCT to improve graft-ver-
sus-leukemia effects.349
ETHYLENECARBODIIMIDE (ECDI) COUPLED ALLOGENEIC ANTIGEN
PRESENTING CELLS INDUCE HUMAN CD41 REGULATORY T CELLS
Magg, T.1, Yu, X.-Z.2, Albert, M.H.1. 1Dr. von Haunersches Kinderspi-
tal der LMU,Munich, Germany; 2H. LeeMoffitt Cancer Center and Re-
search Institute, Tampa, FL.
Adoptive transfer of polyclonal CD41CD251 regulatory T cells
(nTregs) can tolerize transplantation alloresponses and prevent le-
thal acute graft-versus-host disease (GVHD) in mice. However iso-
lation of human CD41CD251 nTregs for adoptive
immunotherapy in sufficient numbers is cumbersome and prone
to contamination with non-regulatory, alloreactive CD251 T-
cells. Incubation of ethylenecarbodiimide (ECDI)-coupled antigen
presenting cells (APC) with naı¨ve T-cells and antigen has been
shown to induce tolerance in various experimental models.
We have therefore hypothesized that ECDI-coupled APC would
be able to tolerize alloreactive naı¨ve human CD41 T-cells from
HLA-incompatible human donors, and have tested whether this
would induce a Treg-like CD41 population (ECDI-Tregs). We
further investigated whether these cells could be expanded ex vivo
without loss of their regulatory capacity.
After 5 days of culture, ECDI-Tregs were as potent as freshly iso-
lated nTregs to suppress proliferation of effector T-cells in a mixed
lymphocyte reaction with allo-APC from the original APC donor
and they maintained high expression of CD62L and CD27 as well
as low CD127 expression. Foxp3 mRNA levels and Foxp3 protein
expression was significantly increased in ECDI-Tregs compared
to cells culturedwith untreated APC or freshly isolatedCD41 cells,
indicating either de novo induction or preferential expansion of
Tregs. ECDI treatment of APC resulted in increased apoptosis
and downregulation of costimulatory molecules CD40, CD80 and
CD86 while HLA-DR expression remained unchanged compared
to untreated cells. This might implicate T-cell receptor - MHC in-teraction without proper costimulation as a possible mechanism for
ECDI-Tregs induction. Addition of IL-2 and rapamycin and
weekly re-stimulation with untreated allo-APC led to exponential
expansion of ECDI-Tregs with increasing foxp3 levels and without
loss of their suppressive activity after 28 days.
These findings provide a proof of principle that ECDI-coupled
allo-APC can induce a potent regulatory T-cell population that
can be expanded ex vivo. These inducible Tregs suggests a novel ap-
proach to enhance the feasibility and effectiveness of inducing toler-
ance by Tregs as an adoptive immunotherapy in transplantation.350
MACROPHAGE MIGRATION INHIBITORY FACTOR AS A NEW TARGET IN
GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION
Chang, Y.-Y.1, Miklos, S.1, Mueller, G.1, Holler, E.1, Lindner, P.2,
Leng, L.3, Schubert, T.4, Bucala, R.3, Hildebrandt, G.C.1. 1University
of RegensburgMedical Center, Regensburg, Germany; 2University of Re-
gensburgMedical Center, Regensburg, Germany; 3Yale University School
of Medicine, New Haven, CT; 4 Institute for Pathology, Frankfurt, Ger-
many.
Acute graft versus host disease (GVHD) is the major complica-
tion after allogeneic (allo) stem cell transplantation (SCT) involving
injury to host tissues by both inflammatory cytokines and donor-de-
rived cellular effectors. Macrophage migration inhibitory factor
(MIF) is produced by various cell types and has a broad range of
proinflammatory properties. We tested, whether MIF contributes
to GVHD by using a well established murine model. Lethally
(1300 cGy) irradiated B6D2F1 (H-2bxd) mice received SCT either
from syngeneic (syn) (B6D2F1) or allo (B6; H-2b) donors. One half
of animals after either syn or allo SCT were treated with polyclonal
antibodies against mouse MIF from day 0 until day 14, whereas the
other halves of syn and allo recipients received control IgG. GVHD
severity was assessed after SCTby survival and a clinical scoring sys-
tem assessing weight changes, fur texture, skin integrity, mobility
and posture. Syn recipients stayed clinically well and all animals sur-
vived regardless their treatment with control or anti-MIF. Animals
receiving allo-SCT plus control IgG developed significant aGVHD
and high mortality. By contrast, in allo anti-MIF treated recipients,
GVHD scores (day 21: 4.4 6 0.4 vs. 5.7 6 0.5) and weight loss
(24.6% vs. 45.4%) were reduced, and survival significantly im-
proved (p\0.05). In addition, target organ injury to the gut (histo-
pathology score: 4.3 6 0.7 vs. 8.0 6 2.6) as well as serum IFNg
(4397 6 995 vs. 6070 6 525 pg/ml) and TNFa (113.9 6 12.7 vs.
159.2 6 22.5 pg/ml) levels of anti-MIF treated allo recipients
were decreased by day 7 when compared to controls. Alloantigen-
specific T cell activation in vitro was significantly suppressed in
the presence of anti-MIF, as determined by a reduction in T cell
proliferation, IFNg and TNFa secretion.
We next challenged syn and allo recipients with P815 lympho-
blast-like mastocytoma cells (H-2d) at the time of transplantation
to asses the effect of anti-MIF on graft versus leukemia (GVL) re-
sponses. Significant P815 cell infiltration was seen after syn SCT
as demonstrated by FACS analysis of the spleens (67.2% infiltra-
tion) and by histopathology of the liver between day 14 and day
21 after SCT. In contrast, P815 cells were significantly cleared in
allo recipients treated with either control or anti-MIF (0.81% and
12.1% infiltration).
In summary, our data show an important role for MIF in GVHD
pathophysiology and suggest MIF as a promising target in reducing
GVHD without the loss of GVL.351
CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) FOLLOWING SIB-
LING DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT)
VERSUS BONE MARROW TRANSPLANT (BMT): GREATER INCIDENCE
AND LONGER DURATION OF IMMUNE-SUPPRESSION (DIS) USING PBSC
Arora, M., Nagaraj, S., DeFor, T.E., MacMillan, M.L., Wagner, J.E.,
Burns, L.J., Weisdorf, D.J. University of Minnesota, Minneapolis, MN.
Poster Session II 129Chronic graft-versus-host disease (CGVHD) is more frequent
following peripheral blood stem cell (PBSCT) than bone marrow
transplantation (BMT). However, the responsiveness of the disease
to immune-suppression using either stem cell source has not been
well validated. We compared the time to discontinuation of im-
mune-suppression between PBSCT and BMT in 184 patients
with CGVHD after sibling donor transplantation. Of 717 sibling
donor transplants (1990–2004), the cumulative incidence of
CGVHD was 25% (95% CI 22–28%) overall and was more fre-
quent after PBSCT [39% (95% CI 32–46%) versus BMT 17%
(95% CI 14–20%), p \ 0.01]. The incidence of discontinuation
of immune-suppression (DIS) was 9% (95% CI 5–13%) at 1 year,
and 67% (95% CI 52–82%) by 5 years [DIS at 1 year: BMT 15%
(95%CI 7–23%) versus PBSCT5% (95%CI 1–9%); and at 2 years:
38% (95% CI 26–50%) versus 32% (95% CI 22–42%); however
both approached 67% by 5 years]. The multivariate analysis was re-
stricted to adult patients who received myeloablative conditioning
(n5 130, 63 BMT, 67 PBSCT) due to interaction between pediatric
age group and stem cell source (17/19 pediatric patients received
BMT); and conditioning regimen and stem cell source (35/37 re-
ceiving non myeloablative conditioning regimen also received
a PBSCT). PBSC recipients, those with progressive onset of
CGVHD and thrombocytopenia (\100,000/ml) at diagnosis of
CGVHD had lower rates of DIS than BM recipients (Table). After
a median follow-up of 33 months, a trend towards superior overall
survival at 5 years was seen in the BMT cohort [5 year survival:
BMT 65% (95% CI 53–75%) versus PBSCT 58% (95% CI 45–
69%) p5 0.07]. Following sibling donor transplantation, CGVHD
is more frequent and more resistant to immune-suppressive therapy
using PBSC vs. BM. PBSC recipients were significantly more likely
to require prolonged immune-suppression and extended morbidity
fromCGVHD.Careful attention to this serious later morbidity and
mortality should guide clinical decisions about the use of either BM
or PBSC sources for sibling donor transplantation.
Time to Hazard Ratio (95% C.I.)
Discontinuation of
Immune Suppression
(.1 5more frequent/
quicker DIS) PStem Cell Source
Marrow 1.0 \0.01
PBSC 0.5 (0.3–0.8)
Onset of CGVHD
Quiescent/Denovo 1.0 0.01
Progressive 0.5 (0.3–0.7)No. of Organs involved
with GVHD
1 1.0
2 0.8 (0.4–1.4) 0.29
31 0.7 (0.3–1.3) 0.21Thrombocytopenia
\100,000/mL 1.0 \0.01
$100,000/mL 2.0 (1.3–3.3)Overall Survival [Kaplan-Meier estimate (95% CI)], p 5 0.07
Marrow PBSCAt 2 years 77% (66–84%) 70% (60–78%)
At 5 years 65% (53–75%) 58% (45–69%)352
EFFICIENT AND SELECTIVE PREVENTION OF GRAFT-VERSUS-HOST DIS-
EASE BY ANTIGEN-SPECIFIC TGFb-INDUCED REGULATORY T CELLS
Yu, X.-Z.1,2, Iclozan, C.1, Anasetti, C.1,2. 1H. LeeMoffitt Cancer Center
& Research Institute, Tampa, FL; 2University of South Florida, Tampa,
FL.
Naturally occurring regulatory T cells (nTregs) suppress the
development of graft-versus-host disease and may spare graft-ver-
sus-tumor effect. As nTreg is a rare cell population in a healthy in-
dividual, using in vitro expanded nTregs is a common strategy to test
their therapeutic potential in hematopoietic cell transplantation
(HCT). However, the concern of in vitro expanded nTregs may in-clude their stability of Foxp3 expression and suppressive function,
survival in vivo, and non-selective suppression of pre-activated
nTregs. In this study, we have used an alternative strategy to gener-
ate antigen-specific, induced Tregs (iTregs). CD41CD25- cells
fromOT-II TCR transgenic, foxp3/gfp knock-in mice were induced
to express Foxp3 by incubating withOVA peptide in the presence of
TGFb. CD41GFP1 cells were purified by sorting and used as
iTregs while CD41GFP- cells as controls. Their ability to prevent
GVHD was tested in a lethally irradiated murine BMT model: B6
/ (B6  bm12)F1. In order to evaluate the specificity of iTregs,
OVA-expressing or non-expressing (B6  bm12)F1 recipients
were compared side by side. We found that iTregs (CD41GFP1)
completely prevented GVHD lethality in OVA1 recipients at
aTreg:Teff ratio of 1:5.The efficacy of these antigen-specific iTregs
were significantly higher than polyclonal nTregs from B6 donors as
they could only partially prevent GVHD and prolong recipient sur-
vival even at a 1:1 ratio. In contrast, iTregs failed to prevent GVHD
in OVA- recipients. As controls, CD41GFP- cells had no effect on
GVHD development in OVA- recipients, and even exacerbated
GVHD in OVA1 recipients compared to B6 CD41 effector cells
alone. These results reveal the therapeutic potential of antigen-spe-
cific iTregs to prevent GVHD efficiently and selectively.353
GENERATION OF TREG-LIKE CELLS FROM CD41CD25- T CELLS VIA EPI-
GENETIC MODIFICATION USING A DEMETHYLATING AGENT DECITA-
BINE
Choi, J., Ritchey, J., DiPersio, J.F. Washington University in St. Louis,
School of Medicine, St. Louis, MO.
Naturally-occurring regulatory T cells (nTreg) contribute to the
maintenance of self-tolerance and have been reported to suppress
autoimmunity and GvHD in mouse models. Major obstacles for
their routine use in human clinical trials include the low number
of Treg, low efficiencies of purification and severe limitations in
ex vivo expansion without downregulating the expression of Foxp3
that is the master gene of Treg. Recent identification of demethy-
lated CpG islands within the Foxp3 locus only in Treg lead us to in-
vestigate whether an FDA-approved demethylating agent,
Decitabine, could be used to enhance expression of Foxp3 via an
epigenetic effect and convert CD41CD25- T cells into Treg. We
incubated human CD41CD25-FOXP3- T cells with anti-CD3/
CD28 beads and hIL-2, followed by Decitabine treatment. Real
time RT-PCR demonstrated levels of mRNA for FOXP3 that
were comparable to that seen in bead-activated nTreg. This resulted
in increased expression at the protein level in 60% of treated cells.
Decitabine also induced Foxp3 expression in 80% of murine
CD41CD25- T cells incubated with anti-CD3/CD28 beads and
hIL-2, followed by Decitabine treatment. The upregulation of
Foxp3 by Decitabine treatment was further validated with GFP ex-
pression in CD41CD25- T cells from Foxp3-ires-GFP KI mice.
The CD41CD25- T cells expanded approximately two fold com-
parable to 13–20 fold of the number of naı¨ve nTreg. These Decita-
bine-treated CD41CD25- T cells (dcT) showed suppressor
function in MLR. We next tested whether these cells were able to
suppressGvHD in an allogeneic BMTmodel.Mice that were trans-
planted with dcT showed significantly higher survival rate and
maintained their weight better. The Treg surface markers, such as
GITR, CTLA4, and CD25 were upregulated in the dcT. We also
found that GzmA and GzmB were upregulated. Using Prf 1 KO
and GzmB KO mice, we found that the suppressor function of
the dcT is partially dependent on Prf 1, but not on GzmB. A
transwell experiment demonstrated that the suppressor function
of dcT is cell-contact dependent. The gene expression profiles
were also compared between dcT, naı¨ve nTreg, and bead-activated
nTreg. We found that dcT expressed high level of CTLA-4,
GITR, CD25, and FR4, which have been known to be upregulated
in nTreg. In summary, Decitabine-treatment of CD41CD25- T
cells enhanced Foxp3 expression. These dcT showed suppressor
function in both in vitro and in vivo and shared part of gene signature
of nTreg.
